Releases
See all
Releases
16. May, 2022
Cessatech reports last patient dosed in pharmacokinetic trial in children of lead candidate
Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing...
Releases
19. April, 2022
First quarter report Q1-2022
Cessatech A/S today releases its results for the period 1 January – 31 March...
Releases
8. March, 2022
Successful outcome from trial 0204
Cessatech reports successful outcome of bioavailability trial 0204 Topline results of clinical trial 0204...
Releases
3. March, 2022
Annual report 2021 published
Cessatech A/S publishes its annual report for the fiscal year 2021. “We managed to...
Releases
6. January, 2022
Changes to the Board of Directors – welcome to Rachel
Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with...
Facts about Children
See all
Facts
15. March, 2022
Off-label use of medication in children continue to be the rule rather than the exception…
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...
Facts
3. March, 2022
Physical restraint of children in 79% of Scandinavian emergency departments
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
Facts
2. February, 2021
Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner
Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...
Facts
8. September, 2020
Behov for større sikkerhed omkring medicin til børn og unge i Danmark
Kun 30% af markedsførte lægemidler i EU er godkendt til børn, og kun 50%...
Facts
31. August, 2020
DR.dk focus – Børn og ældre får medicin, der ikke er godkendt til dem
Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See details
Stay up to date!
Subscribe and get notified on Cessatech's latest news.